MedTrace Logo

Prospective Comparative Study of Hypofractionated Adjuvant Radiotherapy in 2 Virsus 3 Weeks in Breast Cancer

NCT07344597 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2026-01-15

No results posted yet for this study

Summary

To compare the efficacy and safety of two hypofractionated adjuvant radiotherapy regimens 34 Gy in 10

fractions versus 40.05 Gy in 15 fractions in patients with breast cancer treated at the South Egypt Cancer

Institute.

Conditions

Interventions

DEVICE

radiotherapy

Hypofractionated Adjuvant Radiotherapy in 2 versus 3 Weeks of Breast Cancer and effect skin toxicity and over all survival

Sponsors & Collaborators

  • Salwa Shawky Bakeet Ali

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2027-01-31
Completion
2027-02-28

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07344597 on ClinicalTrials.gov